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1003In particular, these data may be important to predict the
number of TAVR candidates, service development, ﬁnancial
planning, and physician training. In addition, estimates of
potential TAVR candidates at intermediate and low surgical
risk are not available. Several factors must be considered
when estimating the number of TAVR candidates: the
percentage of patients with severe AS who are symptomatic;
the proportion of patients with symptomatic severe AS who
do not undergo SAVR and could thus be considered TAVR
candidates; and the percentage of those patients referred for
TAVR who actually receive a transcatheter valve.
Therefore, we sought to assess the prevalence of AS in the
general elderly population (age 75 years) through
a systematic review and meta-analysis of population-based
studies. The second objective was to systematically esti-
mate the number of elderly patients who are TAVR
candidates in both the European countries and North
America.Methods
Studies were identiﬁed through a systematic search of
MEDLINE and EMBASE in February 2012. Keywords
included “valvular heart disease,” “heart valve disease,” “aortic
stenosis,” “aortic valve stenosis,” “epidemiology,” “incidence,”
“prevalence,” and “survey.”No time restrictions were applied.
Reference lists of selected studies and (systematic) reviews
were examined, and the related article feature in PubMed was
used to maximize relevant study identiﬁcation.
All titles and abstracts were screened independently by 2
investigators using the following criteria: 1) the publication
was an original full-length manuscript in a peer-reviewed
journal; 2) the publication reported numbers of AS cases
and sample size or the prevalence of AS in the general elderly
population (75 years of age); and 3) AS and AS severity was
diagnosed with echocardiography (6,7). The deﬁnition of AS
used in each study was extracted, as was other relevant
information including study location, inclusion period, and
patient characteristics. After excluding manuscripts on the
basis of title and abstract, the remaining full-text manuscripts
were carefully assessed and were evaluated according to the
criteria. If overlap between studies existed, only the publica-
tion with the largest population was included. Disagreement
on study inclusion was solved by consensus.
For each included study, the prevalence rate of AS and its
95% binomial conﬁdence interval (CI) was calculated based
on the numbers of subjects in the sample and the number of
patients with AS. These rates were subsequently combined to
produce a pooled prevalence rate of both AS and severe AS.
Both ﬁxed- and random-effects models were used, and results
of the appropriate model are presented as Forest plots. The
ﬁxed-effects model was performed using the inverse variance
method and the random-effects model with the DerSimo-
nian and Laird method. Heterogeneity was assessed by the
Cochran Q test and I2 statistics, derived from the inversevariance ﬁxed-effects model (8).
All analyses were performed with
Stata SE version 12.0 (StataCorp,
College Station, Texas).
Estimation of TAVR candidates.
To estimate the number of el-
derly patients who could po-
tentially be treated with TAVR
under current indications, we
performed a second literature
search on clinical decisionmaking
in patients with severe AS.
Speciﬁcally, we searched for studies that reported: 1) the
percentage of patients with severe AS who experienced
symptoms; 2) the percentage of patients with symptomatic
severe AS who did not undergo SAVR and could thus be
considered potential TAVR candidates; and/or 3) the
percentage of those patients referred for TAVR who actually
received a transcatheter valve. As TAVR is an approved
therapy for patients at high operative risk, we also determined
the proportion of elderly high-risk patients (The Society of
Thoracic Surgery-Predicted Risk Of Mortality [STS-
PROM] score 10%) undergoing SAVR (9), and the
percentage of patients who would be considered TAVR-
eligible. In anticipation of current and potential future trials
in lower risk groups, estimates of the proportion of interme-
diate- and low-risk patients were also derived. For all studies,
the point estimate and 95% binomial CI were calculated.
These data were combined to produce a pooled per-
centage estimate for each individual search. In each case,
a ﬁxed- or random-effects model was used and heterogeneity
was assessed. To calculate national estimates of the number
of patients with AS and TAVR candidates, we obtained
population demographic data focusing on the elderly (75
years of age) for the following nations: Austria, Belgium,
Czech Republic, Denmark, Finland, France, Germany,
Greece, Italy, the Republic of Ireland, Luxembourg, Norway,
Poland, Portugal, Spain, Sweden, Switzerland, the
Netherlands, the United Kingdom, Canada, and the United
States (10–12). The annual number of newTAVR candidates
was calculated using the number of people ages 75 years old in
2011 in the individual countries.
A ﬂowchart was built in TreeAge Pro 2011 (TreeAge
Software, Williamstown, MA). The probabilities in the
ﬂowchart were based on the pooled estimates from the
systematic literature searches. Beta distributions were used
and 10,000 Monte Carlo simulations were performed to
estimate the number of elderly patients who are eligible to
undergo TAVR, along with its 95% percentile CI.
To account for the heterogeneous nature of the studies,
sensitivity analyses were performed. In particular, the
proportion of patients receiving TAVR after referral for
TAVR assessment was determined using European studies
alone and then by combining European and U.S. studies.
This analysis was performed to account for the different
adoption of TAVR in the United States, where until
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1004recently TAVR was only used in the context of clinical trials.
In a second sensitivity analysis, we varied the percentage of
high-risk SAVR-eligible patients who undergo TAVR.Results
The systematic literature search yielded 1,523 studies. After
the title and abstract were screened, 1,408 studies were
excluded because they did not focus on the epidemiology of
disease. After assessing full-text articles, another 109 studies
were excluded because they were not performed in the
general elderly population, AS was not assessed, or because it
was not an original publication. After the inclusion of an
additional study through cross-referencing, our ﬁnal analysis
consisted of 7 studies, with a total of 9,723 elderly patients
(Fig. 1) (1,4,5,13–16). The characteristics of these studies
are outlined in Table 1. The 7 studies reported the preva-
lence of AS in 9 study populations on 3 continents. The
study periods ranged from 1989 to 2009. All studies had
a cross-sectional character, and most were part of larger
population-based cohort studies. In all 7 studies, echocar-
diography was used to diagnose AS, although deﬁnitions of
AS and its severity were variable (Table 1).
The combined prevalence of AS in the elderly was re-
ported in 6 studies and ranged from 2.6% to 22.8%Figure 1 Flowchart of Study Selection
AS ¼ aortic stenosis.(Fig. 2A) (4,5,13,15,16). The pooled prevalence was 12.4%
(95% CI: 6.6% to 18.2%) using a random-effects model
(I2 ¼ 98.5%; Q ¼ 337.70, p < 0.001). The prevalence of
severe AS in the elderly was reported separately in 5 studies
and ranged from 1.2% to 6.1% (Fig. 2B) (1,4,13,14,16). The
pooled prevalence of severe AS was 3.4% (95% CI: 1.1% to
5.7%) using a random-effects model (I2 ¼ 85.7%;
Q ¼ 27.99, p < 0.001).
These estimates of the prevalence of AS in patients 75
years old correspond to approximately 4.9 million elderly
patients with AS in the European countries and 2.7 million
in North America. If only symptomatic severe AS is
considered, this translates to 1.0 million elderly patients in
the European countries and 540,000 in North America. In
2011, 8.5% of the population in the 19 European countries
was 75 years of age, and this number is expected to
increase to 10.7% in 2025 and 16.6% in 2050 (11). In North
America, similar increases in the population demographics
of the elderly are expected (2025, 8.3%, and 2050, 11.8%)
(10,12). These numbers correspond to approximately 1.3
million and 2.1 million patients with symptomatic severe AS
in the 19 European countries in 2025 and 2050, respectively.
In North America, there will be an estimated 0.8 million
and 1.4 million patients with symptomatic severe AS in
2025 and 2050, respectively.
Table 1 Main Study Characteristics of the Included Studies
First Author (Year), Study, Country
Study Design, Study Period,
Population, % Men
Age (yrs) Category
in meta-Analysis
Recruitment Method,
Examination Period
Response Rate (%),
Reasons for Exclusion
Diagnostic Method,
AS Deﬁnition
Lorz (1993),
Switzerland
Cross-sectional study,
70–96 yrs (n ¼ 129),
43% men
70–96, mean 80  6.6
(n ¼ 129)
Random selection within
community and
nursing homes.
1990
51%; death, unable to
contact, and “other reasons”
Doppler echo; all AS: thickening of cusps,
Vmax >1.7 m/s level, or systolic
separation of cusps <15 mm
Lindroos (1993),
Helsinki Ageing Study,
Finland
Cross-sectional substudy
of larger population-based
study, >55 yrs (n ¼ 552),
28% men
75–86 (n ¼ 476) Random selection in
population register.
1990–1991
From complete cohort 84 (9.3%)
persons had died, 21 (2.3%)
could not be contacted, and
144 (16%) refused; 77%
agreed with substudy.
Doppler echo; moderate AS: VR 0.35 and
AVA 1.0–1.2 cm2; severe AS: VR 0.35
and AVA 1.0 cm2; critical AS: VR 0.35
and AVA 0.8 cm2
Stewart (1997),
Cardiovascular Health Study,
USA
Cross-sectional substudy
of larger population-based
study, >65 yrs (n ¼ 5,201),
43% men
>75 (n ¼ 1,736) Random selection
from 4 communities
of Medicare-eligible
patients. 1989–1990
57%; reasons not stated.
Also, subjects with AVR
(n ¼ 23), MVS/MVR/both
(n ¼ 37), BAV (n ¼ 4),
AVE (n ¼ 2), or inadequate
echo data (n ¼ 25) were
excluded.
Doppler echo; all AS: thickened leaﬂets with
reduced systolic opening and Vmax >2.5 m/s
Lin (2005),
Taiwan
Cross-sectional analysis,
20–97 yrs (n ¼ 3,030),
59% of 2,850 group
were men
>80 (n ¼ 82) Persons undergoing routine
physical checkups; those
with severe health conditions
were excluded.
Examination period NR.
NR Doppler echo; all AS: leaﬂet thickening with
reduced systolic opening, gradient
20 mm Hg; severe AS: gradient
>50 mm Hg
Nkomo (2006),*
Olmsted County Cohort,
USA
Cross-sectional substudy of
larger community study,
>18 yrs (n ¼ 16,501),
49% men
>75 (n ¼ 6,663) Patients who underwent
echocardiography
in afﬁliated hospital.
1990–2000
90% of population received
care at afﬁliated hospital.
Doppler echo; Mild AS: Vmax 2.5–3 m/s and
AVA1.5–2 cm2; Moderate AS: Vmax 3–4 m/s
and AVA 1–1.5 cm2; Severe AS: Vmax>4 m/s
and AVA <1.0 cm2
Van Bemmel (2010),
Leiden 85-Plus Study,
the Netherlands
Cross-sectional substudy of
larger population-based
study, >90 yrs (n ¼ 18),
33% men
>90 (n ¼ 81) All inhabitants of Leiden
>85 yrs were invited.
At 90 yrs participants
were invited for echo
examination.
1997–1999
13% of total participants
(n ¼ 705) refused to participate;
71% of 277 participants eligible
for echo were not able to visit
study center.
Doppler echo; mild AS: gradient <25 mm Hg;
moderate AS: gradient 25–40 mm Hg; Severe
AS: Gradient >40 mm Hg
Vaes (2012),
BELFRAIL (BFC80þ),
Belgium
Cross-sectional analysis of
population-based study,
>80 yrs (n ¼ 556)
37% men
>80 (n ¼ 556) 29 general practitioners
in 3 regions included
>80 yr olds.
2008–2009
Severe dementia and medical
emergency patients were
excluded.
Doppler echo; mild AS: AVA >1.5 cm2;
moderate AS: AVA 1.0 cm2–1.5 cm2;
severe AS: AVA <1 cm2
*Only the Olmsted County community study was included in this analysis. Of the 3 pooled population-based studies in this publication, only the Cardiovascular Health Study was eligible and is included in this systematic review (Stewart et al. 1997). The other 2 studies did not
meet the selection criteria because the population studied was too young.
AS ¼ aortic stenosis; AVA ¼ aortic valve area; AVE ¼ aortic valve endocarditis; AVR ¼ aortic valve replacement; echo ¼ echocardiography; MVS ¼ mitral valve stenosis; MVR ¼ mitral valve replacement; NR ¼ not reported; VR ¼ velocity ratio; Vmax ¼ peak velocity.
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Figure 2 Forest Plots on the Prevalence of AS
(A) Mild, moderate, and severe aortic stenosis (AS) in the elderly, using a random-effects model. I2 ¼ 97.1%, Q ¼ 140.25, p < 0.001. (B) Severe AS in the elderly, using
a random-effects model. I2 ¼ 85.7%, Q ¼ 27.99, p < 0.001. CI ¼ conﬁdence interval.
Osnabrugge et al. JACC Vol. 62, No. 11, 2013
Aortic Stenosis Epidemiology and TAVR Candidates September 10, 2013:1002–12
1006Estimates of TAVR candidates. The number of elderly
patients who could potentially beneﬁt from TAVR was esti-
mated using the model outlined in Figure 3, with inputs from
the systematic search andmeta-analyses (Fig. 4). Seven studies
reported the percentage of patients with severe AS who were
symptomatic, resulting in a pooled estimate of severe symp-
tomatic AS of 75.6% (95% CI: 65.8% to 85.4%) (Fig. 4A,
Online Table 1). Of these patients with symptomatic severe
AS, 40.5% (95%CI: 35.8% to 45.1%) did not undergo SAVR
and thus could be considered candidates for TAVR (Fig. 4B,
Online Table 2). Nine studies reported the percentage of
patients referred for TAVR who actually received a trans-
catheter valve (Online Table 3). Three of these studies were
performed in Europe, and 6 in the United States. The pooledpercentage including both European and U.S. studies was
28.7% (95% CI: 22.8% to 34.6%) (Figs. 4C and 4D, respec-
tively). The European pooled percentage was 40.3% (95% CI:
33.8% to 46.7%), whereas the U.S. pooled percentage was
24.4% (95% CI: 18.9% to 29.8%). In total, 12.3% of patients
with symptomatic severe AS at prohibitive surgical risk are
TAVR candidates.
To assess the proportion of elderly SAVR patients who
was deemed to be at high surgical risk, we used a study that
reported on all elderly SAVR patients in the United States
between 1999 and 2007 (17). Among elderly patients
undergoing isolated SAVR, 5.2% (95% CI: 4.9% to 5.4%)
were at high risk (STS-PROM 10%), 15.8% (95% CI:
15.4% to 16.2%) at intermediate risk (STS-PROM 5% to
Figure 3 Model for the Estimation of TAVR Candidates Among the Elderly
AS ¼ aortic stenosis; SAVR ¼ surgical aortic valve replacement; STS-PROM ¼ The Society of Thoracic Surgery Predicted Risk of Mortality; TAVR ¼ transcatheter aortic valve
replacement.
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100710%), and 79.1% (95% CI: 78.6% to 79.5%) at low
risk (STS-PROM <5%). A recent study showed that in
a group of operable patients with a EuroSCORE (Euro-
pean System for Cardiac Operative Risk Evaluation) 15,
approximately 80% were treated with TAVR (18).
In 2011, there were 39,316,978 people 75 years of age
in the European countries and 21,182,683 in North
America (10–12). Combining these ﬁgures with the Monte
Carlo simulations in the model (Fig. 3), we estimated that
a total of 292,000 high- or prohibitive-risk elderly patients
with symptomatic severe AS are candidates for TAVR.
Speciﬁcally, there are 189,836 (95% CI: 80,281 to 347,372)
TAVR candidates in the European countries and 102,558
(95% CI: 43,612 to 187,002) in North America. Annually
there are 17,712 (95% CI: 7,590 to 32,691) new TAVR
candidates in the European countries and 9,189 (95% CI:
3,898 to 16,682) in North America. The total and annual
number of TAVR candidates in the individual countries is
presented in Figures 5 and 6, respectively.
The intermediate surgical risk group comprises approxi-
mately 145,000 elderly patients with symptomatic severe AS.
Speciﬁcally, there are 94,730 (95% CI: 40,574 to 171,896)
patients at intermediate risk in the European countries and
50,733 (95% CI: 22,148 to 90,451) in North America. The
low surgical risk group includes approximately 730,000
patients with symptomatic severe AS. Speciﬁcally, there are477,314 (95% CI: 206,798 to 862,958) patients at low-risk in
the European countries and 255,727 (95% CI: 108,549 to
460,026) in North America.
Sensitivity analyses. In the pre-speciﬁed sensitivity analysis
that varied the proportion of patients receiving TAVR after
referral for TAVR assessment according to study location
(28.7%, 95% CI: 22.8% to 34.6% in Europe and the United
States combined), we estimated that approximately 220,000
patients are TAVR candidates. Of these, 142,658 (95% CI:
61,065 to 263,795) candidates lived in the European countries
and 76,962 (95% CI: 32,805 to 140,673) in North America.
In the sensitivity analysis varying the percentage of high-
risk operable patients who would undergo TAVR, the total
number of TAVR candidates was 277,570 (95% CI: 119,406
to 512,707) assuming that 50% would undergo TAVR
whereas there were 302,865 (95% CI: 129,433 to 550,562)
candidates if all the high-risk patients would undergo TAVR.
Finally, we estimated that the total number of patients with
symptomatic severe AS in the intermediate-risk category was
145,936 (95%CI: 62,802 to 263,340), and 733,861 (95%CI:
310,623 to 1,302,586) in the low-risk category.Discussion
The current study found that the prevalence of AS in the
elderly (75 years of age) is 12.4%, and severe AS is present
Figure 4 Forest Plots of the Different Steps in Estimation Model
(A) Severe aortic stenosis (AS) and symptomatic; (B) not treated with surgical aortic valve replacement (SAVR), potentially treatable with transcatheter aortic valve replacement
(TAVR); (C) treated with TAVR, European studies; and (D) treated with TAVR, all studies. CI ¼ conﬁdence interval.
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1008in 3.4%. Among elderly patients with severe AS, 75.6% are
symptomatic, and 40.5% of these patients are not treated
surgically. From those, 40.3% are potentially treated with
TAVR. In total, 12.3% of the prohibitive risk group are
TAVR candidates. Among patients undergoing SAVR for
severe symptomatic AS, 5.2% are high risk and 80% of those
are potential TAVR candidates. Based on these data, we
estimated that there are currently approximately 190,000
and 100,000 TAVR candidates in the European countries
and North America, respectively. Each year, approximately
18,000 new TAVR candidates emerge in the European
countries and 9,000 in North America.
The prevalence of AS. Our estimates of the prevalence
demonstrate that the overall burden of disease due to AS in
the general elderly population is substantial. Population
demographics clearly show that Western populations are
aging, thereby further increasing the impact of AS. No
effective medical therapy is available for patients with AS,
and if not treated by intervention, the estimated 5-year
survival of severe AS is only 15% to 50% (7). These datasuggest that the treatment of AS in the elderly will have an
increasing impact on public health and health care resource
consumption in the future.
Based on echocardiographic diagnosis, we found that
severe AS occurs in 12.4% of the general elderly (75 years
of age) population. Previous autopsy series and a study based
on aortic valve diagnoses in Medicare claims have reported
AS prevalence estimates of 9.2% and 16%, respectively
(19,20). Our pooled prevalence of AS (12.4%) is lower than
the estimates from Medicare claims, but covered a lower age
group and did not include diagnoses of aortic regurgitation.
The methodological differences between studies are likely to
account for the variability in AS estimates.
We explored heterogeneity by assessing the individual
study characteristics, but the limited number of studies
prevented separate analyses. The heterogeneity is reﬂective
of different diagnostic deﬁnitions for AS, dissimilar re-
cruitment methods, and varying study periods (Table 1).
Study participation was only 50% to 60% in 2 studies,
making their results vulnerable for selection bias (5,15). In
Figure 5 Total of TAVR Candidates in Different Countries Under Current Treatment Indications
*Due to the simulation process, the totals are not exactly the same as the sum of the individual countries. CI ¼ conﬁdence interval; TAVR ¼ transcatheter aortic valve
replacement.
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10091 study, AS was diagnosed using clinically indicated echo-
cardiography (1). That might have caused a lower
prevalence rate of AS. Moreover, improvements of echo-
cardiographic techniques and interobserver variability might
have had an inﬂuence on the prevalence rates and
heterogeneity.
The number TAVR candidates. Nearly 40.5% of all
patients with symptomatic severe AS did not undergo
SAVR (Fig. 4B). Possible explanations for the lower than
expected rates of SAVR include excessive operative risk,
advanced age, comorbidities, and patient preference (21,22).
TAVR is a safe, effective, and less invasive treatment
strategy for a highly selected proportion of the patients
who do not undergo SAVR (23), represented by the 40.3%
of patients who underwent TAVR (Fig. 4C). The treat-
ment decisions reﬂect heart team discussions, in which
(interventional) cardiologists and cardiac surgeons combinerisk models with additional factors such as frailty, porcelain
aorta, and vessel tortuosity (24).
The estimated large number of TAVR candidates has
clinical, economic, and social implications. If the index
admission costs (US $72,000) of the PARTNER (Place-
ment of Aortic Transcatheter Valves) trial are applied (25),
treating all TAVR candidates would represent a budget
impact of $13.7 billion in the European countries and $7.2
in North America. At a price of $30,000, the total device
turnover would be approximately $8.7 billion. Although
TAVR is cost effective in the United States for patients at
high and prohibitive risk (25,26), data from other countries
show that, for intermediate-risk patients, the costs of
TAVR at 1 year are considerably higher than the costs
of SAVR (27). Importantly, cost is not the only factor
that determines the adoption of novel technologies such as
TAVR (28). Reimbursement strategies, physician training,
Figure 6 Annual Number of TAVR Candidates in Different Countries Under Current Treatment Indications
*Due to the simulation process, the totals are not exactly the same as the sum of the individual countries. CI¼ conﬁdence interval; TAVR¼ transcatheter aortic valve replacement.
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this costly technology.
Despite budgetary concerns, current clinical trials are
evaluating TAVR for patients at intermediate surgical risk
(NCT01314313 and NCT01586910) (9,29). If TAVR
proves to be noninferior to SAVR in this population, we
estimate that a further 145,000 patients would becomeTAVR
eligible. Indeed, there is some evidence that suggests that
TAVR is already being performed in these intermediate-risk
patients (18,30). Thus, our estimates of the impact of posi-
tive outcomes in the ongoing trials are likely to be conservative.
In the future, TAVR may even compete with SAVR in
patients at low surgical risk (30,31), a group that comprises
730,000 severe AS patients in the European countries and
North America combined.
TAVR learning curve analyses show increasing proﬁ-
ciency with evidence of plateau after the ﬁrst 30 cases (32).In addition, governmental bodies mandate that each TAVR
center performs at least 20 to 50 TAVR procedures per year
(33–35). These requirements, combined with the ﬁgures
from this study, are useful to estimate the number of TAVR
centers and physicians who need to be trained in TAVR in
the individual countries. For example, the 526 (95% CI: 224
to 965) new TAVR candidates per year in the Netherlands
justify approximately 10 certiﬁed centers, assuming that each
center performs 50 cases annually. Similarly, the 8,205 (95%
CI: 3,470 to 15,139) new TAVR candidates per year in the
United States suggest a requirement of approximately 165
certiﬁed TAVR centers.
The divergent standards of medical evidence required
to introduce new therapies in Europe and the United
States are likely to account for the difference in TAVR
dissemination between the continents (36). Although the
Edwards Sapien valve (Edwards Lifesciences, Inc., Irvine,
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1011California) and Medtronic CoreValve (Medtronic, Inc.,
Minneapolis, Minnesota) both received the Conformité
Européenne (CE) mark in 2007, the U.S. Food and Drug
Administration used trial data to approve the Edwards
Sapien valve for patients at prohibitive and high surgical risk
only in November 2011 and October 2012, respectively.
Consequently, TAVR has been performed with greater
frequency and for a wider range of indications in Europe
than in the United States. The studies on decision making in
patients with AS reﬂect the commercial use of TAVR in
Europe, whereas the U.S. studies display decision making in
a time when TAVR use was restricted to clinical trials.
These differences in practice are likely to disappear after the
commercialization of TAVR in the United States and were
taken into account in our sensitivity analyses.
Study limitations. Although we systematically searched
the literature, relatively few reports on the prevalence of
AS in the general population were identiﬁed. Additional
population-based studies that use a uniﬁed echocardio-
graphic deﬁnition of AS are warranted. The current study,
however, reﬂects all of the currently available evidence on
the prevalence of AS.
The estimation of TAVR candidates is as accurate as the
currently available inputs and assumptions from the litera-
ture. However, we used sensitivity analyses to assess the
inﬂuence of uncertain parameters. In addition, we included
measures of uncertainty in each step of the model to
calculate conﬁdence intervals, representing the likelihood of
the ﬁnal estimates.Conclusions
This systematic review and meta-analysis of population-
based studies found that the prevalence of AS and severe
AS among the elderly is 12.4%, and 3.4%, respectively. The
overall burden of disease due to severe AS in the general
elderly population is substantial. Our model showed that
under the current indications approximately 290,000 elderly
patients at high or prohibitive surgical risk could potentially
be treated with TAVR in Europe and North America, and
that each year there are approximately 27,000 new TAVR
candidates. These estimates have considerable clinical,
economic, and social implications.Acknowledgments
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